Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis

Chemotherapy

Volumn 51, Issue 5, 2005, Pages 252-255

  Asencio, M A ^a   Garduno E ^a   Perez Giraldo C ^b   Blanco, M T ^b   Hurtado, C ^b   Gomez Garcia A C ^b  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Candida parapsilosis; Proteinase inhibitors; Secreted aspartyl proteinases

Indexed keywords

ALBUMIN; ASPARTIC PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CANDIDA PARAPSILOSIS; COW; DRUG EFFICACY; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; YEAST;

ASPARTIC ENDOPEPTIDASES; CANDIDA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; RITONAVIR; SAQUINAVIR;

EID: 23944465904     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087252     Document Type: Article

References (23)

1. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer S, Houston A, Coffman S, Hollis R: International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999;35:19-25.
2. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ: Bloodstream infections due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000;44:747-751.
3. Anil S, Samaranayake LP: Brief exposure to antimycotics reduces the extracellular phospholipase activity of Candida albicans and Candida tropicalis. Chemotherapy 2003;49:243-247.
4. Egusa H, Ellepola ANB, Nikagawa H, Hamada T, Samaranayake LP: Exposure to subtherapeutic concentrations of polyene antifungals suppresses the adherence of Candida species to denture acrylic. Chemotherapy 2000;46:267-274.
5. Cassone A, De Bernardis F, Mondello F, Ceddia T, Agatensi L: Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987;156:777-783.
6. De Bernardis F, Mondello F, San Millán R, Pontón J, Cassone A: Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol 1999;37:3481-3486.
7. De Bernardis F, Arancia S, Morelli L, Hube B, Sanglard D, Schäfer W, Cassone A: Evidence that members of the secretory aspartyl proteinase gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999;179:201-208.
8. Borg-von Zepelin M, Meyer I, Thomssen R, Würzner R, Sanglard D, Telenti A, Monod M: HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 1999;113:747-751.
9. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R: In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180:448-453.
10. Monod M, Borg-von Zepelin M, Telenti A, Sanglard D: The inhibition of Candida albicans secreted aspartic proteases by three different HIV protease inhibitors. Dermatology 1999;198:412-414.
11. Munro CA, Hube B: Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol 2002;10:173-176.
12. Pichová I, Pavlicková L, Dostál J, Dolejsí E, Hrusková-Heidingsfeldová O, Weber J, Ruml T, Soucek M: Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Eur J Biochem 2001;268:2669-2677.
13. Ray TL, Payne CD: Comparative production and rapid purification of Candida acid proteinase from protein-supplemented cultures. Infect Immun 1990;58:508-514.
14. Blanco MT, Hurtado C, Pérez-Giraldo C, Morán FJ, González-Velasco C, Gómez-García AC: Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases. Med Mycol 2003;41:1-4.
15. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
16. Dostal J, Hamal P, Pavlicková L, Soucek M, Ruml T, Pichová I, Hrusková-Heidingsfeldová O: Simple method for screening Candida species isolates for the presence of secreted proteinases: A tool for the prediction of successful inhibitory treatment. J Clin Microbiol 2003;41:712-716.
17. Serda A, Yücel A: Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains. Mycoses 2002;45:160-165.
18. Wu T, Samaranayake LP: The expression of secreted aspartyl proteinases of Candida species in human whole saliva. J Med Microbiol 1999;48:711-720.
19. Yamamoto T, Nohara K, Uchida K, Yamaguchi H: Purification and characterization of secretory proteinase of Candida albicans. Microbiol Immunol 1992;36:637-641.
20. Gottfredsson M, Cox GM, Indridason OS, De Almeida G, Heald AE, Perfect JR: Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999;180:534-537.
21. Korting HC, Schaller M, Eder G, Hamm G, Böhmer U, Hube B: Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 1999;43:2038-2042.
22. Gruber A, Speth C, Lukasser-Vogl E, Zangerle R, Borg-von Zepelin M, Dierich MP, Wurzner R: Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 1999;41:227-234.
23. Diz Dios P, Ocampo A, Otero I, Iglesias I, Martínez C: Changes in oropharyngeal colonization and infection by Candida albicans in human immunodeficiency virus-infected patients. J Infect Dis 2001;183:355-356.